No Detail Found!

Comparison of Topical Silymarin with Hydroquinone in theTreatment of Melasma

Author(s)
Sumaira Abdullah Department of Dermatology, Islamabad Medical and Dental College, Islamabad, Pakistan
Mahwish Ahmed Department of Dermatology, HBS Medical and Dental College, Islamabad Pakistan
Mahvish Aftab Khan Department of Dermatology, Rawal General and Dental Hospital, Islamabad, Pakistan
Tayaba Iqbal Leighton Hospital, Crewe, England.
Shawana Sharif Department of Dermatology, Benazir Bhutto Hospital, Rawalpindi.Pakistan
Farhat Rehman Department of Dermatology, Islamabad Medical and Dental College, Islamabad, Pakistan
Abstract
To compare the efficacy and safety of topical silymarin 0.7% with topical hydroquinone 4% in the treatment of melasma. Place and Duration: This Randomized Controlled Trial was conducted at the dermatology OPD of Akbar Niazi Teaching Hospital, Bara Kahu, Islamabad, for a period of one year from April 2020 to April 2021. Materials and Methods: Female patients having melasma were included in the study. The severity of melasma was assessed using the MASI score. Group A was treated with silymarin 0.7% cream and group B was treated with topical hydroquinone 4% cream. Treatment was given for 3 months and was followed up for the next 3 months to observe relapse. Clinical efficacy was assessed in terms of the percent reduction in MASI score from baseline. Results: The mean age in group A (Silymarin 0.7%) was 35.13 ± 3.87 and in group B (Hydroquinone 4%) was 34.16 ± 3.90. Epidermal type of melasma was most common (76.8% vs 62.5%) in both groups. There was no significant (p-value > 0.05) difference between both groups after one and two months of treatment but the mean MASI score of the Hydroquinone 4% group (10.59 ± 5.74) became significantly (p-value < 0.05) less than Silymarin 0.7% group (8.20 ± 4.41) after 3 months. Similar (p-value > 0.05) therapeutic response was observed after one and two months of treatment but it became significantly better in Hydroquinone 4% group after three months of treatment. Significantly (P-value < 0.05) higher adverse effects were detected in patients treated with hydroquinone. There was no significant difference (P-value > 0.05) in recurrence rate and patients satisfaction between both groups. Conclusion: Topical silymarin has comparable efficacy for the treatment of melasma with comparatively very less adverse effects as compared to hydroquinone.
Publication Details
Page(s) 90-95
Published Journal: Journal of Rawalpindi Medical College, Volume: 26, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
silymarin, Melasma, Melasma, MASI score, Hydroquinone
0

Citations

0

Downloads

43

Views